Slide 1: Investor Presentation September 2023
For personal use only Investor Presentation September 2023 Human & Animal Programs 1
Slide 2: Better technology more life
For personal use only Better technology more life Our mission is to develop and commercialise superior reproduction and fertility solutions for humans and animals 2
Slide 3: Disclaimer
Disclaimer This presentation is not and does not form part of any offer, invitation or recommendation in respect of securities. Any decision to For personal use only buy or sell Memphasys securities or other products should be made only after seeking appropriate financial advice. Reliance should not
Slide 4: Why Memphasys?
Why Memphasys? Pipeline of unique human and animal products co-developed with Memphasys’ Professor John For personal use only 1 Aitken, Scientific Director and world-renowned leader in fertility 2 Product R&D strategy exclusively addressing unmet demand in global reproductive technology markets 3 Cl
Slide 5: Distinguished Emeritus Professor John Aitken
Distinguished Emeritus Professor John Aitken ▪ A global leader in reproductive biology, heading up his research team For personal use only at University of Newcastle. ▪ Leads the development of MEM’s pipeline products to proof-of- concept stage. ▪ *Ranked #1 in the world in the cell biology of sperm
Slide 6: Pipeline
Pipeline For personal use only RoXsta* (Rapid in vitro antioxidant assessment) AI-Port Early access (animal use has low regulatory barriers) Early access for animal. Highly regulated for human * Formerly named ROSA; trademark application pending 6
Slide 7: Set for growth
Set for growth For personal use only New Opening New Pipeline Talent Markets Patents Building ▪ Director Business ▪ Exclusive FelixTM System ▪ New patents granted in ▪ Prof John Aitken Development distribution agreement Australia to support (Scientific Director) & ▪ Director Operations with Vitrolif
Slide 8: Felix System: Better technology for IVF sperm preparation
Felix™ System: Better technology for IVF sperm preparation For personal use only Console Ongoing, repeat revenue from single-use cartridge* * A new cartridge is used for each semen sample 8
Slide 9: Felix System: Sperm separation principles
Felix™ System: Sperm separation principles: High sperm negative charge and size exclusion membranes Allows ion transfer but blocks sperm passage For personal use only Raw semen Processed semen Separates sperm from other cell types Mature, negatively charged sperm harvested after 6 mins 9
Slide 10: Felix System: Better technology
Felix™ System: Better technology For personal use only Electrophoretic system Easy 6-minute process selects sperm with both low DNA damage & oxidative stress Single-use, disposable cartridge Can process wide quality range of semen samples One-step and automated 10
Slide 11: Felix System: Proven efficacy
Felix™ System: Proven efficacy ▪ Peer review publications ▪ Live healthy births - and For personal use only from highly damaged sperm ▪ Improved sperm quality ▪ Rapid and easy to use 11
Slide 12: Felix System: First recorded births in India
Felix™ System: First recorded births in India* ▪ All couples had poor prognosis for success: For personal use only ▪ All suffering from failed repeat cycles ▪ Highly damaged sperm** ▪ Some had recurrent pregnancy loss ▪ Clinical results to date:*** ▪ Embryo transfers: 40 ▪ Clinical pregnancies :14 ▪
Slide 13: New Japanese partnership with Vitrolife, Japan
New Japanese partnership with Vitrolife, Japan Exclusive distribution of the Felix™ System For personal use only 13
Slide 14: Global fertility decreasing – males account for ~50%
Global fertility decreasing – males account for ~50% For personal use only ▪ 1 in 6 couples experience fertility issues A. Average total fertility rate Fertility rate (births per women) 5.5 ▪ Sperm dysfunction is the single most common cause of 5 4.5 infertility 4 ▪ Sperm counts decreasing 3.5 3 ▪ S
Slide 15: Increased demand for assisted human reproduction
Increased demand for assisted human reproduction For personal use only Three regions – Asia, Europe and N America - constitute ~90% of the global market https://www.icmartivf.org/wp-content/uploads/ICMART-ESHRE-WR2018-Preliminary-Report.pdf 15
Slide 16: Global ART: Top market contributors
Global ART*: Top 10 market contributors (ascending order) China Japan ~17% of the global market For personal use only India USA Russia Spain France Germany Italy Australia *Assisted Reproduction Technology 16 https//www.cnbctv18.com
Slide 17: Global market opportunity: ~A$2 billion
For personal use only Global market opportunity: ~A$2 billion https://www.icmartivf.org/wp-content/uploads/ICMART-ESHRE-WR2018-Preliminary-Report.pdf 17
Slide 18: Early access market opportunity: ~A$31 million
Early access market opportunity: ~A$31 million For personal use only CANADA ~A$2m JAPAN ~A$28m NZ ~A$1m https://www.icmartivf.org/wp-content/uploads/ICMART-ESHRE-WR2018-Preliminary-Report.pdf 18
Slide 19: Sales pathway in early access markets
Sales pathway in early access markets For personal use only Regulatory Local distributor Pre-sales Sales Hurdles appointed Japan ✔︎ ✔︎ ✔︎ ✔︎ NZ ✔︎ ✔︎ Canada ✔︎ Other (Developing countries Seeking specialist e.g. Bangladesh, Sri regulatory advice Lanka) 19
Slide 20: Sales pathway in highly regulated markets: 2024-25
Sales pathway in highly regulated markets: 2024-25 Regulator Pre-submission Clinical trials Comments For personal use only Anticipated completion Australia TGA ✔︎ 3-4Q FY24 n/a In-country (TGA) approval Australian Clinical is standard pathway India CDSCO ✔︎ trial anticipated to Investigating earlier
Slide 21: Monash IVF Trial: Progress and path to TGA registration
Monash IVF Trial: Progress and path to TGA registration For personal use only Results % Complete: analysis and Anticipated TGA Swim up arm 95% Trial completion regulatory file approval to DGC arm: 25%* Review submission market Q3/Q4 FY2024 Q4 FY2024 Q3 FY2025 * New Monash IVF site in Perth recently
Slide 22: Felix System: Advantages over traditional methods
Felix™ System: Advantages over traditional methods Conventional DGC (Density Gradient Felix™ System Centrifugation) and/or swim-up processes* For personal use only Process: 30-60+ minutes Rapid - six minutes Multi-step & labour intensive Single vessel & automated Specialised clinical operators Easy
Slide 23: RoXsta: a rapid in vitro antioxidant assessment
RoXsta*: a rapid in vitro antioxidant For personal use only assessment * Formerly titled ‘ROSA’ 23
Slide 24: Oxidative Stress: A serious chemical imbalance
Oxidative Stress: A serious chemical imbalance For personal use only ANTIOXIDANTS CELLULAR EXTERNAL ADVERSE METABOLISM Cellular reactions Healthy diet Free radical + FACTORS Ageing/Stress Specific oral formulations generation Environmental Toxins Unhealthy Lifestyle GENERATION OF ‘ROS’ (Reactive Oxy
Slide 25: Reductive Stress: An equally serious chemical imbalance
Reductive Stress: An equally serious chemical imbalance ▪ Chronic antioxidant For personal use only overdosing ▪ Elevated levels of biochemical reductants ▪ Reduced testosterone production ▪ Cellular energy dysregulation 25
Slide 26: The adverse effect of oxidative/reductive stress imbalance
The adverse effect of oxidative/reductive stress imbalance Oxidative stress Reductive stress For personal use only ▪ Aging ▪ Chronic inflammatory disease ▪ Heart failure ▪ Impaired sperm production ▪ Cancer ▪ Neurogenesis inhibition and maturation ▪ Neurodegenerative disease ▪ Decreased cellular met
Slide 27: RoXsta: Fills unmet diagnostic need
RoXsta: Fills unmet diagnostic need For personal use only Current practice Memphasys Testing for oxidative stress is rare: Testing is easy with Memphasys: ▪ Complex equipment ▪ Simple point of care diagnostic device ▪ Time-consuming in lab ▪ Six-minute process ▪ Oxidative stress often undiagnosed ▪
Slide 28: RoXsta: Stage of development
RoXsta: Stage of development Proof of concept established by Prof. John Aitken’s research team at University of Newcastle For personal use only ▪ ▪ RoXsta comprises 4 separate assays* all using the same fundamental device structure to measure different aspects of antioxidant activity ▪ The developme
Slide 29: RoXsta: Indicative Path to Market
RoXsta: Indicative Path to Market For personal use only 29
Slide 30: Potential uses of RoXsta
Potential uses of RoXsta User group Application Fertility researchers ▪ Researching underlying etiology of infertility & gestational issues For personal use only IVF clinics ▪ Screening for infertility issues in male and female patients ▪ Diagnosing and monitoring the progress of pregnancy; detectin
Slide 31: RoXsta: Addressable market estimated at >$10 billion
RoXsta: Addressable market estimated at >$10 billion Application Size For personal use only Fertility researchers $3m IVF clinics $3b Obstetricians, urologists, endocrinologists $4b Food technology industry $3b Other applications e.g. clinicians specialising in other TBD disease states, consumer use
Slide 32: RoXsta: Pathway to market
RoXsta: Pathway to market Requirements prior to selling For personal use only Application Industry Verification & Small Regulatory KOL testing validation studies clinical trial approval Early sales Fertility research market ✔︎ potential Food industry monitoring ✔︎ Diagnostic fertility market (male &
Slide 33: AI-Port: Aim is to increase cattle pregnancy rates with AI
AI-Port: Aim is to increase cattle pregnancy rates with AI For personal use only 33
Slide 34: Artificial insemination is the most efficient method to improve herd genetics
Artificial insemination (AI) is the most efficient method to improve herd genetics ▪ Initial target: beef cattle - growing need to improve genetics in high end cattle breeds e.g. wagyu, Black Angus For personal use only ▪ Later applications: high end dairy, horse* (non-thoroughbred) Degree of herita
Slide 35: AI technology is antiquated and needs improvement
AI technology is antiquated and needs improvement Current AI process For personal use only Step 1 Step 2 Step 3 Step 4 Semen Sperm count, motility and Semen cryopreserved at Semen straws are kept in collection morphology assessed -196 oC. liquid nitrogen until they are Cryopreservation causes requir
Slide 36: MEM's new protocol to prepare sperm for AI without freezing
MEM’s new protocol to prepare sperm for AI without freezing For personal use only Step 1 Step 2 Step 3 Viable motile sperm Semen collection Toxic seminal plasma is removed No freezing Simple centrifugation to remove the Sperm extended in MEM’s seminal plasma proprietary medium for up to 4 days 36
Slide 37: Spring 2023 pregnancy comparison field trial
Spring 2023 pregnancy comparison field trial Step 1 Step 2 Step 3 For personal use only Frozen semen 150 cows Current industry method 3-4 bulls from stud Raw ejaculate Isolated (centrifugation) 150 cows in NSW Hunter extracted sperm cells in MEM’s AI- New method region Port medium Higher pregnancy e
Slide 38: Indicative AI-Port Pathway to Market
Indicative AI-Port Pathway to Market For personal use only Next steps after field trial, assuming positive result: ▪ MEM will manufacture the media in-house and then seek to sell AI-Port in the next breeding season to Australian producers ▪ MEM will also prepare access for selling in overseas market
Slide 39: AI-Port – Potential accessible market ~ A$2.4 billion
AI-Port – Potential accessible market ~ A$2.4 billion For personal use only Cattle CANADA (mostly diary) 3% EU JAPAN US 30% 2% 12% BRAZIL 47% AUSTRALIA & NEW ZEALAND 6% APPROXIMATE SIZE OF TOP SIX AI BEEF MARKET BY COUNTRY/ REGION 1, 2 1 Extracted multiple sources: Grandview Research–Veterinary AI M
Slide 40: Better technology More life
Better technology More Lifemore life For personal use only 40
Slide 41: Appendices
For personal use only Appendices 41
Slide 42: RoXsta is a quick (5 minute), novel point-of-care diagnostic
RoXsta is a quick (5 minute), novel point-of-care diagnostic • Uses include rapid measurements of different antioxidant activities and optimum doses use only Examples of three antioxidants with different levels of antioxidant activity* 2 Low: Antioxidant no. 1 2 Moderate: Antioxidant no. 2 High: Ant
Slide 43: Felix System patents & trademarks
Felix™ System patents & trademarks PATENTS For personal use only MEMPHASYS REFERENCE APPLICANT COUNTRY TITLE CASE STATUS EXPIRY Cell Separation Memphasys Limited US Cell Separation Granted (3 Jan 2012) 14-Jul-26 Electrophoresis Separation (CN) Memphasys Limited China Electrophoresis Device Granted (
Slide 44: Financial snapshot as of September 2023
Financial snapshot as of 15 September 2023 For personal use only KEY DATA1 A$ OWNERSHIP STRUCTURE1 % Share price 0.015 Peters Investments 27.2 Shares on issue 959.5M A Goodall 18.7 Market capitalisation 14.4M A Coutts 8.8 Top 20 55.6 CONVERTIBLE NOTES Peters Investments 3M (at A$3M face value & matu
Slide 45: Experienced leadership team
Experienced leadership team For personal use only Robert Cooke Alison Coutts Paul Wright Andrew Goodall CHAIRMAN CEO NE DIRECTOR NE DIRECTOR Professor John Aitken Pablo Neyertz Dr. David Ali Assoc. Prof. Hassan Bakos DIRECTOR RESEARCH DIRECTOR FINANCE DIRECTOR BUSINESS DIRECTOR OPERATIONS DEVELOPMEN